Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori
| Autor: | Ali N Hussain, Muhammad Ameen, Madhavi Ravi, Kishore Kumar, Hassan Tariq, Vamshidhar Vootla, Danial Shaikh, Vamsi Amanchi, Jasbir Makker, Sara Azam, Harish Patel, Naeem Abbas, Muhammad Umar Kamal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Population Single Center Gastroenterology 03 medical and health sciences 0302 clinical medicine Levofloxacin Internal medicine Clarithromycin medicine education education.field_of_study biology business.industry Helicobacter pylori bacterial infections and mycoses biology.organism_classification medicine.disease Regimen 030220 oncology & carcinogenesis Peptic ulcer 030211 gastroenterology & hepatology Gastritis medicine.symptom business medicine.drug |
| Zdroj: | Clinical and Experimental Gastroenterology. 13:25-33 |
| ISSN: | 1178-7023 |
| DOI: | 10.2147/ceg.s239343 |
| Popis: | Background Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge. Aim There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population. Methods This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy. Results A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001). Conclusion In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|